Other relevant news · Mind Medicine Australia
Mind Medicine Australia logo Menu

Other relevant news

EXCLUSIVE: Florida Lawmaker Introducing Psilocybin Mushroom Legalization

Forbes, 15 January, 2021

A Florida state lawmaker plans to introduce as soon as next week a bill that would legalize psilocybin-assisted therapy in the state.

Read more

Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO

CNBC, 15 January, 2021

Headquartered in Berlin, ATAI is aiming to make psychedelic medicines that can be used to treat mental health disorders. Recognify, meanwhile, is specifically aiming to make a medicine that can be used to treat the cognitive impairment associated with schizophrenia, or CIAS.

Read more

Talking Music, Ceremony and Psychedelic-Assisted Therapy with Tania de Jong AM

Rune Soup, 13 January, 2021

Listen now

Mount Sinai Health System Launches Center for Psychedelic Research

Psychedelic Finance, 08 January, 2021

New York, Ny (January 07, 2021) The Icahn School of Medicine at Mount Sinai has launched a new center for psychedelics research. The Center for Psychedelic Psychotherapy and Trauma Research pursues a multipronged clinical and research approach to discovering novel and more efficacious therapies for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related conditions in the veteran and civilian population.

Read more

COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care

Globe News Wire, 08 January, 2021

Read more

Why Investors Are Psyched About Psychedelic Stocks

Visual Capitalist, 07 January, 2021

Psychedelic stocks are trading like biotechnology companies these days. The prospect of promising research has pushed valuations upwards.

Read more

Big pharma is about to tune in to the potential of psychedelics

Wired, 01 January, 2021

Mainstream mental-health care will embrace alternative active substances such as psilocybin.

Read more

Why Canada Could Be Next To Allow Psychedelic Therapy (And How It’s Already Changing Lives)

Forbes, 30 December, 2020

Now, as a handful of patients and more recently doctors and therapists have been granted exemptions to use psilocybin, the nation’s federal health agency is considering making changes to existing policies that could open the door to much more than magic mushrooms.

Read more

Psychedelic drug DMT to be trialled in UK to treat depression

The Guardian, 10 December, 2020

Exclusive: UK regulators give go-ahead for drug to be trialled ahead of possible treatment alongside psychotherapy.

Read more

New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression

UC Davis, 09 December, 2020

A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California, Davis. A paper describing the work is published Dec. 9 in Nature.

Read more

Health care professionals okayed to use magic mushrooms for training in psilocybin therapy

Now Toronto, 09 December, 2020

Psychologists, psychiatrists, social workers and nurses are among 17 health care professionals granted the exemption by Health Canada this week.

Read more

Can the active ingredient in magic mushrooms help treat anxiety? Researchers want to know.

The Age, 08 December, 2020

Australia is embarking on one of the world’s largest studies into the use of psychedelic drugs for mental health, with Melbourne researchers preparing to launch a world-first clinical trial investigating whether psilocybin – the active ingredient in “magic mushrooms” – can help treat people suffering severe persistent anxiety.

Read more

Silo Pharma Plans Phase 2B Trial Testing Low-dose Psychedelics in Parkinson’s

Parkinson's News Today, 04 December, 2020

Silo Pharma is collaborating with Maastricht University on a Phase 2b clinical trial to investigate the effects of low-dose psychedelics on cognitive and emotional dysfunction in patients with Parkinson’s disease.

Read more

United Nations approves WHO recommendation to reschedule cannabis in historic vote

Marijuana Business Daily, 02 December, 2020

The United Nations Commission on Narcotic Drugs (CND) accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.

Read more

Psilocybin Treatment for Mental Health Gets Legal Framework

Scientific American, 01 December, 2020

Oregon became the first state to legalize therapeutic use of the drug, as new research affirms its benefits for treating depression.

Read more

'The war on drugs failed': California lawmaker will push to decriminalise psychedelics

The Guardian, 20 November, 2020

A California lawmaker has announced he will take on the arduous battle to decriminalize psychedelics in the state, citing Oregon, which voted to decriminalize hard drugs and legalize psilocybin, and the District of Columbia, which has decriminalized psychedelics, as inspiration.

Read more

Jewish psychedelics advocate working to turn drug into legal medicine

The Jerusalem Post, 20 November, 2020

In the United States, research on these chemicals has been banned since the 1960s because, in the government’s judgment, they have no recognized medical value.

Read more

Psilocybin for Depression Study Approved and Funded by German Government

Psilocybin Alpha, 19 November, 2020

The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.

Read more

Canada Is Allowing People With Depression to Do Psychedelic Mushrooms

Vice World News, 17 November, 2020

The Canadian government is allowing patients who are not terminally ill to legally consume psychedelic mushrooms.

Read more

What the U.S. Military’s $27M investment in psychedelic drugs could mean for veterans with PTSD

The Dales Report, 11 November, 2020

The U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) has invested nearly USD $27 million into a team of researchers led by professor of pharmacology Dr. Bryan L. Roth at the University of North Carolina School of Medicine.

Read more

Washington, DC, just decriminalized psychedelic plants. Here’s what happens next

Leafly, 04 November, 2020

Residents of the nation’s capital just took a step toward more liberal use of hallucinogens, in response to a groundswell of interest in new drugs for medical maladies.

Read more

Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in ‘psychedelic renaissance’

CNBC, 04 November, 2020

Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.

Read more

Oregon Measure 109, Psilocybin Mushroom Services Program Initiative (2020)

Ballotpedia, 03 November, 2020

Oregon Measure 109, the Psilocybin Program Initiative was on the ballot in Oregon as an initiated state statute on November 3, 2020. It was approved. Learn more here.

Read more

Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms

Forbes, 23 October, 2020

Read more

Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms

Forbes, 23 October, 2020

Read more

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

Plos One, 14 October, 2020

Read more

Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

MAPS, 14 October, 2020

Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $(USD)103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients.

Read more

What if a Pill Can Change Your Politics or Religious Beliefs?

Eddie Jacobs, Scientific American, 11 October, 2020

Read more

The New Yorker: Turn On, Tune In, Get Well

The New Yorker, 12 October, 2020

New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center.

Read more

PsyTech Hosts Live Investor Conference & Webinar October 27, 2020 and Closes Transaction with One of the Largest Psychedelic Conferences PsyTech.biz

Global News Wire, 25 September, 2020

PsyTech Summit 2020 will be a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. Mind Medicine Australia Executive Director, Tania de Jong AM will be presenting alongside other distinguished speakers associated with Mind Medicine Australia including Professor David Nutt, Dr Rick Doblin, Professor Matthew W. Johnson, Dr Robin Carhart-Harris, Dr Adele Lafrance and Dr Reid Robison.

Read more

The Washington Post: Who Will Benefit From Psychedelic Medicine?

Washington Post, 21 September, 2020

Who Will Benefit From Psychedelic Medicine? These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

Read more

Mind Medicine CEO Calls Compass IPO: A 'Clear Bellwether' For Psychedelic Space

Bezinga, 19 September, 2020

On Friday, UK-based mental health care company Compass Pathways NASDAQCMPS announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange.

Read more

IntelGenx inks double deals to develop oral film psychedelics for psychiatric use

Fierce Pharma, 16 September, 2020

Drug delivery specialist IntelGenx has penned two deals to develop film-based, prescription psychedelics amid a surge of interest—and investment—from the biopharma industry.

Read more

UC Berkeley launches center for psychedelic science and education

Berkeleyside, 18 September, 2020

UC Berkeley launches center for psychedelic science and education With $1.25M in seed funding, the new center will conduct research using psychedelics to investigate cognition, perception and emotion and their biological bases in the human brain.

Read more

Usona Puts New Psilocybin Synthesis Method in the Public Domain

Ann Harrison, 15 September, 2020

The nonprofit Usona Institute has developed a new technique to synthesize kilograms of pharmaceutical grade psilocybin and placed this information in the public domain where it cannot be patented.

Read more

Psychedelics For CNS Disorders: Understanding The Opportunity

Ben Comer, 09 September, 2020

Investigational uses of psilocybin and MDMA – two illicit drugs associated with recreational use and abuse in the US – will soon enter the later stages of clinical development for the treatment of CNS disorders including depression, addiction and post-traumatic stress disorder.

Download the article here as a PDF.

Read more

Why Psychedelics Must be Legalized and Normalized: A Patients and Human Rights Argument

Eliott Edge, Medium, 11 October, 2018

Downlad the article here as a PDF.

Read more

Breaking the stigma: Psychedelic Drugs

Cannabis Life Network, 22 August, 2020

There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine). As they are, indeed, physiologically toxic and addictive. Psychedelics, on the other hand, have been mistaken to have the same, or even worse detrimental effects to one’s health.

Read more

Silicon Valley and Wall Street Elites Pour Money Into Psychedelic Research

The Wall Street Journal, 20 August, 2020

A group of Silicon Valley and Wall Street executives has raised $30 million to speed the development of a closely watched psychedelic-drug therapy using the key ingredient of the party drug Ecstasy to treat trauma patients.

Read more

Psychedelic Science in Post-Covid Psychiatry

DocWire News, 19 August, 2020

The medium to long term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19.

Read more

Eleusis sheds light on psychedelics that relieve asthma in rats with no mental effects

Fierce Biotech, 13 August, 2020

Psychedelic drugs like LSD have long been of interest in the medical community because of their anti-inflammatory properties. But efforts to transform them into therapeutics have been hampered by laws restricting the use of psychedelics, not to mention the stigma associated with them.

Read more

The first Canadian to legally consume psilocybin for medical purposes shares his experience

Regina Leader-Post, 21 August, 2020

Earlier this month, four Canadians received Section 56 exemption to the Controlled Drugs and Substances Act, allowing them to pursue psilocybin therapy for end-of-life distress.

Read more

Canada Will Let Terminally Ill Patients Use Psychedelic Mushrooms For End-Of-Life Care

CNN, 06 August, 2020

Four cancer patients in end-of-life care will be become the first people in decades to legally possess and consume psilocybin mushrooms in Canada after a landmark decision.

Read more

The Current Status of Psychedelics in Psychiatry

Dr David Nutt and Dr Robin Carhart-Harris, American Medical Association, 29 July, 2020

The Current Status of Psychedelics in Psychiatry

Download (47.3 KB)

Psilocybin Therapy for Addiction

60 Minutes USA, 21 July, 2020

Anderson Cooper sits down with Jon Kostakopoulos to discuss his experience as a clinical participant in an NYU psilocybin study treating alcohol use disorder.

Read more

Psilocybin & OCD: Can psychedelics treat obsessive compulsive disorder?

New Atlas, 23 July, 2020

A new review from neuroethicist Eddie Jacobs, and published in the Journal of Psychedelic Studies, is suggesting psilocybin may have great potential as a treatment for obsessive-compulsive disorder (OCD).

Read more

Lucy in the sky with diamonds

https://www.vogue.pt/english-version-lucy-sky-diamonds, 20 July, 2020

LSD, psilocybin, ecstasy, ayahuasca. From happy trips of the past to mental health of the present, could psychedelics be the future of therapy?

Read more

Magic mushrooms could help ex-soldiers to overcome trauma

The Guardian, 04 July, 2020

As more troops self-medicate with psychedelic drugs to help with PTSD, a group of experts lobby for proper clinical trials.

Read more

We can no longer ignore the potential of psychedelic drugs to treat depression

https://www.theguardian.com/commentisfree/2020/jun/08/psychedelic-drugs-treat-depression, 08 June, 2020

Imperial College, UK have been comparing psilocybin to conventional antidepressants – and the results are likely to be game-changing


Dr Robin Carhart-Harris is a member of the Mind Medicine Australia advisory panel.

Read more

COVID-19 impact likely to lead to increased rates of suicide and mental health

Dr Tony Bartone, Professor Ian Hickie AM, Professor Patrick McGorry AO, AMA Joint Statement, 02 June, 2020

Australia will likely see increases in youth suicide and a surge in demand for specialist mental health services as the full and lasting impact of the COVID-19 pandemic is experienced across the community.

Read more

Psychedelics v. Cannabis: In Search of a Better Business Plan

David H., The Cannabis Investor, May 27, 2020, 27 May, 2020

Organizations forming today will build the infrastructure which, three to five years from now, will be delivering psychedelic medicines to the world.

Read more

Interim Analysis Shows At Least 90% Chance of Statistically Significant Difference in PTSD Symptoms after MDMA-assisted Psychotherapy

Brad Burge, Multidisciplinary Association for Psychedelic Studies (MAPS), 13 May, 2020

Results are the strongest confirmation that an interim analysis can provide

Read more

Psychedelic Pioneer Rick Doblin On FDA Trials Of MDMA: Most Important Reality Check Of MAPS’ 34-Year History

David E. Carpenter, Forbes, 12 May, 2020

Read more

Revolutionary drug trial could see ecstasy used as prescription medicine for those living with PTSD and mental illness

Sarah Abo, 60 Minutes Australia, 10 May, 2020

Read more

Psychedelic Drugs Can Improve Quality Of Life - And Death - For Older Adults

Abbie Rosner, Forbes, 06 May, 2020

Read more

Are Psychedelics Our Most Promising New Treatments for Depression, Anxiety, and Addiction?

Paul Tullis, Town&Country, 13 April, 2020

Read more

German Government Funds Psilocybin Study for Depression

Mind and Brain Institute, 24 April, 2020

Read more

Coronavirus mental health fallout: Rapid response like psychedelic therapy need of the hour?

Vinay B.S., International Business Times, 13 April, 2020

Read more

Can psychedelic therapy reduce the mental health impacts of the coronavirus pandemic?

Morgan Campbell, The Sacramento Bee, 02 April, 2020

Read more

This New York City Pharma Startup Wants To Turn LSD Into An FDA-Approved Medicine For Anxiety Disorder

Will Yakowicz, Forbes, 01 April, 2020

Read more

Coronavirus impact on mental health 'seven times' bushfire anxiety

Dana McCauley, The Sydney Morning Herald, 26 March, 2020

Download the article here as a PDF.

Read more

Eleusis Announces Published Preclinical Research Revealing Long Lasting Antidepressant-Like Effects of Psychedelics When Compared to Ketamine in Animals

Carol Guaccero, Business Wire, 05 March, 2020

Read more

Business gets ready to trip: How psychedelic drugs may revolutionize mental health care

Jeffrey M. O'Brien, Fortune, 19 February, 2020

Read more

Microdosed LSD: Finally A Breakthrough For Alzheimer’s Disease?

Abbie Rosner, Forbes, 21 February, 2020

Read more

Psychedelics for systems change: could drugs help us save the planet?

Jules Peck, openDemocracy, 15 February, 2020

Read more

Move over, pot: Psychedelic companies are about to go public

Kristine Owram, Bloomberg News, 11 February, 2020

Read more

Study: Psilocybin From Magic Mushrooms Plus Therapy Delivers Benefits Nearly Five Years Later

David DiSalvo, Forbes, 31 January, 2020

Read more

Could psychedelics help us resolve the climate crisis?

Matthew Adams, The Conversation, 28 January, 2020

Download the article as a PDF here.

Read more

Antianxiety And Antidepressant Effects From A Single Dose Of Psychedelic Drug Persist Years Later In Cancer Patients

Shira Polan, Science Mag, 28 January, 2020

Read more

Psychedelics: Can getting high improve your mental health?

Sandee LaMotte, CNN, 20 January, 2020

Read more

MDMA inches away from becoming FDA-approved Pharmaceutical

The Waking Times, 20 January, 2020

Read more

MDMA treatment for alcoholism could reduce relapse, study suggests

The Guardian, 19 August, 2019

Read more

Psychedelics Create New Communication Pathways In The Brain ( Homological Scaffolds )

Beckley Foundation, 17 November, 2017

Watch our brains become more connected on psilocybin, and learn how psychedelics can help treat conditions such as depression, addiction, and PTSD.

Read more

Transforming psychedelics into mainstream medicines

Shlomi Raz, Stat News, 07 January, 2019

Download (211.8 KB)

The future of psychedelic science: What the next decade holds

Rich Haridy, New Atlas, 26 December, 2019

Read more

A New Way To Quit? Psychedelic Therapy Offers Promise For Smoking Cessation

Stephanie O'Neill, NPR, 22 December, 2019

Read more

MDMA-assisted couples therapy: How a psychedelic is enhancing intimacy and healing PTSD

Anne Wagner, The Conversation, 20 December, 2019

Read more

MMA Advisory Panel members Dr Robin Carhart-Harris and Dr Rosalind Watts have joined the Advisory Board for Synthesis Retreat in the Netherlands

Jessica McCulloch, 09 December, 2019

Read more

Microdosing LSD for Alzheimer’s proves safe in early human trial

Rich Haridy, New Atlas, 18 December, 2019

Read more

Psilocybin for major depression granted Breakthrough Therapy by FDA

Rich Haridy, The Atlas, 24 November, 2019

Read more

The Return Trip: Psychedelics may come back from the abyss of illegality

Peter Stilla, Valley Advocate, 20 November, 2019

Read more

Psilocybin-assisted therapy for depression: How do we advance the field?

David Castle, Australian & New Zealand Journal of Psychiatry, 19 November, 2019

Read more

Magic mushroom compound psilocybin shows promise for treatment of anxiety and depression

Robyn Williams, The Science Show, ABC Radio National, 11 November, 2019

Read more

Health Report with Norman Swan

Dr Norman Swan, On Breakfast Program with Hamish Macdonald, ABC Radio National, 11 November, 2019

Research into psychedelic drugs like LSD is growing, encouraged by positive early trials. Scientists think these drugs could treat things like post-traumatic stress disorder and depression.

Download the interview here as an mp3.

Read more

What Happened When I Sought Alternative Mental Health Treatment Abroad

Lizbeth Finn-Arnold, The Mighty, 11 November, 2019

Read more

Why Psychedelics Could be the Future of Anorexia Treatment

Tessa Love, Elemental Medium, 06 November, 2019

Read more

Clinical Trials Show Antidepressants “Not Beneficial in the Long Term”

MAD in America, 07 October, 2019

Read more

Researchers Gene-Hacked E. Coli to Produce Psilocybin

Futurism, 03 October, 2019

Read more

Field Trip Ventures Inc. Partners with the University of the West Indies to Create the World's First Legal Research and Cultivation Facility for Psilocybin

PR Newswire, 19 September, 2019

Read more

Magic Mushrooms As Medicine? Johns Hopkins Scientists Launch Center For Psychedelic Research. Say Psychedelics Could Treat Alzheimer’s, Depression And Addiction.

Forbes Magazine, 12 September, 2019

Read more

Usona Institute Clinical Trial of Psilocybin for Major Depressive Disorder Launching This Fall

Business Wire, 09 September, 2020

Read more

Tim Ferris, the man who put his money behind psychedelic medicine

Benedict Carey, The New York Times, 09 September, 2019

Read more

John Hopkins opens new center for Psychedelic Research

Benedict Carey, The New York Times, 05 September, 2019

Read more

Magic Mushroom Psilocybin being Researched as Aid for Alzeimer's & Depression

Andrew Whalen, Newsweek, 04 September, 2019

Read more

World-first trial investigating psilocybin psychotherapy for anorexia commencing in US

Rich Haridy, New Atlas, 27 August, 2019

Read more

Why Psychiatry Needs Psychedelics and Psychedelics Need Psychiatry

Journal of Psychoactive Drugs, Ben Sessa, 11 March, 2014

Read more

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia: